Greenwich LifeSciences (GLSI) Invested Capital (2019 - 2020)
Greenwich LifeSciences' (GLSI) quarterly Invested Capital came in at $275154.0 in Q4 2020, down 56.68% YoY from $635154.0 in Q1 2020, and down 56.68% on a QoQ basis from $635154.0 in Q3 2020.
Powered by 
Analysis
Greenwich LifeSciences (GLSI) Invested Capital (2019 - 2020) Analysis & Trends
Greenwich LifeSciences (GLSI) has 2 years of Invested Capital data on file, last reported at $275154.0 in Q4 2020.
- Quarterly Invested Capital fell 56.68% year-over-year to $275154.0 in Q4 2020, while the trailing twelve-month figure through Sep 2021 was $275154.0 (down 78.34% YoY) and the FY2020 annual result came in at $275154.0, down 56.68% from the prior year.
- Invested Capital eased to $275154.0 in Q4 2020, from $635154.0 in the prior quarter.
- In the past five years, Invested Capital ranged from a high of $12.0 million in Q3 2019 to a low of $275154.0 in Q4 2020.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Invested Cap. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 33.70 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | 7.35 Bn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 6.25 Bn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | - |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 19.13 Bn |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | 1.30 Bn |
| 10 | Greenwich LifeSciences | 231.59 Mn | 231.59 Mn | - | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Dec 31, 2020 | 27.91 Mn |
| Sep 30, 2020 | 5.29 Mn |
| Dec 31, 2019 | -715,264.00 |
| Sep 30, 2019 | 10.79 Mn |